Immunocore’s ImmTAV Shown to Redirect the Immune System to Kill HIV-Infected Cells from Patients Treated with Antiretroviral Therapy
- Data published in peer-reviewed Molecular Therapy demonstrate Immunocore’s new class of bispecific antiviral reagents, ImmTAVs, can recruit T cells to kill HIV-infected CD4+ T cells
- Persistence of latent HIV in CD4+ T cells is a major barrier to eradication
- First demonstration of the potential for an ImmTAV to treat infectious diseases
Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that positive new data have been published that demonstrate the potential of a novel antiviral drug created by Immunocore to harness the immune system to kill HIV-infected cells.